演題詳細

一般口演 / Oral Session

一般口演 107 (Oral Session 107) :ウイルス感染症/血球貪食症候群

print

日程
2013年10月13日(日)
時間
15:00 - 16:00
会場
第14会場 / Room No.14 (札幌市教育文化会館 3F 研修室305)
座長・司会
森 慎一郎 (Shinichiro Mori):1
1:聖路加国際病院 血液腫瘍内科
 
前へ戻る

Monitoring EBV reactivation in Severe Aplastic Anemia treated with rabbit ATG

演題番号 : OS-3-183

那須 健太郎 (Kentaro Nasu):1、福原 規子 (Noriko Fukuhara):1、猪倉 恭子 (Kyoko Inokura):1、小野寺 晃一 (Kouichi Onodera):1、斉藤 陽 (You Saitou):1、八田 俊介 (Shunsuke Hatta):1、鈴木 真紀子 (Makiko Suzuki):1、中嶌 真治 (Shinji Nakajima):1、沖津 庸子 (Yoko Okitsu):1、勝岡 優奈 (Yuuna Katsuoka):1、大西 康 (Yasushi Onishi):1、藤原 亨 (Toru Fujiwara):1、木幡 桂 (Kei Kohata):2、山本 譲司 (Joji Yamamoto):2、亀岡 淳一 (Junichi Kameoka):1、石澤 賢一 (Kenichi Ishizawa):1、張替 秀郎 (Hideo Harigae):1

1:Department of Hematology and Immunology, Tohoku University、2:Sendai City Hospital

 

Background: Reactivation of Epstein-Barr virus (EBV) during immunosuppressive therapy can cause serious complications. Method: We retrospectively analyzed consecutive, newly diagnosed severe aplastic anemia (SAA) who received rabbit antithymocyte globulin (ATG) / Cyclosporine between 2011 and 2012. We monitored peripheral blood EBV viral load by real-time polymerase chain reaction. Results: Seven SAA patients aged 18 to 66 (median: 33) were studied. EBV reactivation was observed in 5 out of 7 patients [peak 275-20,000 copies/μgDNA]. Among the patients with subclinical EBV reactivation (n=4), peaks of EBV viral load were observed on day 32-42 (median: 35) and turned negative on day78-172(median: 123). ATG dose of patients without EBV reactivation (3.0mg/kg and 3.2mg/kg; n=2) were lower than that of patients with EBV reactivation (3.75mg/kg; n=4, 2.5mg/kg; n=1). One patient developed EBV-related diffuse large B-cell lymphoma on day 38. Rituximab monotherapy was given and complete remission was achieved. Conclusion: Our data showed that EBV reactivation after ATG therapy peaked at about 7 weeks and could be affected by the dose of ATG.

前へ戻る